AURIGENE
PHARMACEUTICAL SERVICES

SUCCESS STORY

Engineering bispecific drug products

From aggregation prone to conformationally stable

The Challenge

AURIGENE
PHARMACEUTICAL SERVICES

Stable formulation required in the range of low to high concentration, without impacting viscosity

Conformational stability needed across both Lyo and Liquid presentations

Compressed timelines requiring rapid buffer, pH and excipient assessment

AURIGENE
PHARMACEUTICAL SERVICES

Our Approach

We rebuilt the synthesis end-to-end:

Drug Product Development

- Excipient evaluation across both Lyophilized and Liquid presentations
- Fill volume studies for improved DP presentation and manufacturability
- Development of optimized lyophilization recipe

AURIGENE
PHARMACEUTICAL SERVICES

The Impact

Aggregation profile < 1%
across stability conditions

Moisture < 2%
in final Lyo DP

Reduced development timelines 40% from Industry average

Faster Manufacturability
cGMP DP batch within 4 weeks

AURIGENE
PHARMACEUTICAL SERVICES

Scale-Up Success

Buffer & pH identified in 14 days
Rapid screening informed final formulation

3-month accelerated stability
Delivered for both Lyo and Liquid presentations



AURIGENE
PHARMACEUTICAL SERVICES

Unlock complex bispecific drug product challenges

If you're facing hurdles in formulation, lyophilization, or stability of complex biologics, we'd be happy to explore solutions with you.

Connect with us to discuss your program

Discover how Aurigene can accelerate your development journey